Journal of Biotechnology & Biomaterials
Open Access

Abstract

The evidence for the critical clinical repercussions stemming from the simultaneous, dys-regulated expression of multiple components within both the pro-inflammatory and chemoresistance pathways is evermore present within a large spectrum of cancer conditions. The author?s team is currently investigating the level of dys-regulated gene expression of hallmark pro-inflammatory genes within multiple, validated chemoresistanttumour cell line models such as neuroblastoma, breast and prostate carcinomas.In essence, identification of these novel interplays can demonstrate to contribute key diagnostic and prognostic biomarkers that can serve the oncology clinician to take more informed clinical decisions, based on the individual tumour characteristics. Such informed clinical decisions ultimately allow for bespoke and enhanced therapeutic efficacy, possibly utilising current anti-inflammatory drug treatments, with minimal suffering to the individual cancer patient presenting with chemoresistanttumours.

Biography

Duncan Ayers has completed his PhD in Translational Medicine from The University of Manchester (UK) and is currently continuing his postdoctoral studies at The University of Malta. He is also a Research Associate with the Faculty of Medicine & Human Health Sciences at the University of Manchester. During his doctoral studies, he also spent a 17-month attachment with the Vandesompele group at the Center for Medical Genetics Ghent (Ghent University, Ghent, Belgium). He has published/presented his research in more than 34 reputed journal papers and international meetings, together with contributing to four book publications